Can ketamine treat depression after a stroke?

Ketamine has a strong record in treatment-resistant depression, and post-stroke depression is frequently treatment-resistant, so it is a reasonable candidate to consider. The stroke-specific evidence, though, is still early: it consists mainly of a small case series in people plus animal studies, not large controlled trials. We treat it as an option worth discussing after a careful evaluation, not as a proven therapy for depression that followed a stroke.

Is ketamine safe for someone who has had a stroke?

Safety depends heavily on the individual, and blood pressure is the central concern. Ketamine can transiently raise blood pressure and heart rate during an infusion, which matters more in someone with a vascular history. That is why we review the type and timing of the stroke, current blood pressure control, medications, and cardiovascular status closely before considering treatment, and why we monitor vital signs throughout. Someone in the acute aftermath of a stroke is not a candidate for outpatient ketamine; the people we would consider are well into recovery and living with persistent low mood.

Why is depression after a stroke so hard to treat?

Post-stroke depression is not simply grief over a health setback. A stroke damages brain tissue and disrupts the circuits and chemistry that regulate mood, and it triggers inflammation that can linger. On top of that biological injury, people are often coping with new physical limits, communication difficulty, and fatigue. Standard antidepressants help some patients but leave many others still depressed, which is part of why researchers have started looking at treatments that work through a different mechanism, like ketamine.

How soon after a stroke could ketamine be considered?

There is no established protocol, because the research is early. What we can say is that outpatient ketamine for mood is meant for people who are stable and well past the acute event, with blood pressure under good control and medical clearance in hand. The reported human experience used it as an add-on to standard care in people already in the recovery phase. Timing is one of the specific things we work through during a consultation, ideally in coordination with your neurologist or primary care provider.

Does ketamine help the brain recover after a stroke, or just lift mood?

It is important to separate the two. Ketamine's antidepressant effect is well established in general, and early stroke-specific reports focus on relieving depression symptoms. The idea that ketamine directly aids brain recovery after a stroke—by calming neuroinflammation, restoring synaptic connections, and boosting BDNF—comes largely from animal research. That is a promising line of science, but it is not proven in stroke patients, and we would not present ketamine as a treatment that repairs stroke damage.

Ketamine for Post-Stroke Depression

A stroke rearranges a life in an afternoon. The rehabilitation that follows—relearning words, regaining a grip, steadying a walk—gets most of the attention, and it should. But there’s a quieter complication that often goes under-treated: the depression that settles in during recovery and refuses to lift. For a lot of families in Middle Tennessee, that flat, heavy mood becomes the thing that stalls everything else.

Post-stroke depression is common, it’s serious, and it’s frequently stubborn against standard medication. That combination is why ketamine has started to come up in these conversations. We want to lay out what’s actually known, including the parts that aren’t settled, because a topic this personal deserves straight talk rather than salesmanship.

How Common Is Depression After a Stroke

Depression is one of the most frequent psychiatric consequences of a stroke. Large reviews put the figure at roughly one in three survivors experiencing depression at some point in the years afterward. It can appear in the first weeks or emerge months into recovery, and it’s tied to worse outcomes across the board: slower physical rehabilitation, more difficulty with daily tasks, greater strain on caregivers, and higher mortality.

Part of what makes it easy to miss is that everyone expects a stroke survivor to feel down. Some sadness is understandable. But post-stroke depression is more than a reasonable reaction to a hard event—it’s a distinct clinical condition with a physical basis, and it responds to treatment when it’s recognized.

Why It’s So Hard to Treat

Two things are happening at once after a stroke, and both feed depression.

The first is direct injury. A stroke destroys brain tissue and disrupts the networks and neurochemistry that regulate mood, motivation, and emotional control. It also sets off an inflammatory response that can persist long after the initial event. So the depressed brain after a stroke isn’t just a sad brain—it’s an injured one, with altered signaling in the very circuits antidepressants are trying to reach.

The second is the lived reality of recovery: new physical limits, trouble with speech or memory, fatigue, loss of independence, and sometimes isolation. That psychological weight sits on top of the biological injury.

Standard antidepressants, mostly SSRIs, do help a share of patients and remain a sensible first step. But many people stay depressed despite them, and the medications take weeks to work—weeks during which rehabilitation may be slipping. That gap between need and result is exactly where interest in a different mechanism comes from.

Why Ketamine Is a Logical Candidate

Most antidepressants nudge serotonin and take their time. Ketamine acts on the glutamate system through the NMDA receptor and, downstream, appears to restore synaptic connections within hours to days. We go deeper into this in our explainer on how ketamine works, but the core idea is that it engages the brain’s capacity to rebuild healthy connections—the same capacity that both depression and stroke tend to degrade.

Ketamine has a well-established track record in treatment-resistant depression. Since post-stroke depression is so often treatment-resistant by nature, it follows that researchers would ask whether ketamine’s benefit carries over to this specific group. That question is now being studied, though the work is early.

What the Research Actually Shows

Here’s where it’s worth slowing down and being precise, because two different claims tend to get blurred together.

The first claim is that ketamine can relieve depressive symptoms in people who are recovering from a stroke. The direct human evidence here is genuinely preliminary. In 2025, researchers published what they described as the first documented case series of ketamine used for post-stroke depression—a small number of patients given short-term intravenous ketamine as an add-on to standard care, delivered over several sessions across about four weeks at the familiar subanesthetic dose. A case series is a signal, not proof; it points a direction for larger controlled trials rather than settling the question.

The second claim is more ambitious: that ketamine helps the stroke-injured brain itself recover. This idea rests mostly on animal research. In mouse models of post-stroke depression, S-ketamine reduced depression-like behavior while calming neuroinflammation, restoring synaptic function in the prefrontal cortex, and activating the BDNF pathway.

In a post-stroke depression model, S-ketamine ameliorated depression-like behaviors via attenuation of neuroinflammation, synaptic restoration, and activation of the BDNF pathway. — Summarized from 2025 preclinical research, Biochemical and Biophysical Research Communications

That’s a compelling mechanism, and it lines up with what we understand about ketamine and neuroinflammation and ketamine and BDNF more broadly. But animal findings don’t automatically translate to people, and we don’t present ketamine as a treatment that repairs stroke damage. What we can speak to responsibly is the mood side of the equation.

It’s also worth keeping perspective. Ketamine research overall has produced some mixed results, including a 2025 trial in which serial infusions didn’t outperform placebo in a hospitalized population. That doesn’t erase the strong body of evidence in treatment-resistant depression, but it’s a healthy reminder that ketamine isn’t a guarantee for anyone, and least of all in an area where the specific research is just beginning.

The Safety Question That Comes First

With stroke, the safety conversation centers on blood pressure. Ketamine can transiently raise blood pressure and heart rate during an infusion. In most healthy adults that’s a manageable, well-monitored effect, but in someone with a vascular history it deserves real attention, since the same risk factors that led to a stroke—hypertension, cardiovascular disease—are the ones we watch during treatment.

A few practical points follow from that:

Someone in the acute aftermath of a stroke is not a candidate for outpatient ketamine. The people we would consider are well into recovery and living with persistent low mood.
We review the type and timing of the stroke, current blood pressure control, cardiovascular status, and every medication before deciding anything.
Vital signs are monitored continuously throughout each infusion, and we’re prepared to manage blood pressure if it climbs.
We prefer to coordinate with your neurologist or primary care provider rather than work in isolation.

You can read more about how we think through candidacy in is ketamine therapy safe and about the cases where we say no in when we decline ketamine for a patient. A stroke history doesn’t automatically rule treatment out, but it does raise the bar for a careful, individualized evaluation.

How We’d Approach It

If depression has taken hold since a stroke, a thoughtful evaluation looks at the full picture: when and what kind of stroke, what deficits remain, how blood pressure is controlled now, what antidepressants have already been tried, and what other medications are on board. Because communication and cognition can be affected after a stroke, the environment of the infusion matters—calm, unhurried, and supported. That’s part of why Marla stays present during infusions, and why our therapy dogs, Walter White and Wilma, are part of the room.

The stretch of hours and days after each session, the neuroplastic window, is worth treating with intention as well. Gentle routine, rest, and supportive follow-up—often alongside ongoing stroke rehabilitation—can help any mood gains take root. A depressed stroke survivor who starts to feel lighter often engages more fully in the physical therapy that recovery depends on, and that ripple effect is one of the reasons treating post-stroke depression matters so much.

An Honest Bottom Line

Depression after a stroke is common, damaging, and frequently resistant to the first medications people try. Ketamine offers a different mechanism, a real record in treatment-resistant depression, and an early but promising line of research aimed at the post-stroke population. What we won’t do is overstate it. The human evidence here is a small case series, the brain-repair story is still mostly in animals, and blood pressure makes careful screening essential.

If you’re carrying a low mood that took hold after a stroke—or watching a family member disappear into one—we’d be glad to talk it through honestly, with a clear line between what the science has established and what it’s still working out. You can also learn more about our approach to depression treatment generally.